Combination therapy for relapsed pediatric solid tumors
Part of Cancer clinical trials.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 18 years old.
- Your cancer (neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, or similar) has come back after treatment or hasn't been stopped by standard therapy.
- You need to have at least one tumor that can be measured on a CT or MRI scan.
- Your blood counts, kidney function, and liver function must be within a certain range (your doctor will check these).
- You cannot be pregnant, breastfeeding, or in another clinical trial at the same time.
- You must not have severe heart problems, active infections, or allergies to any of the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three chemotherapy drugs (irinotecan liposomes, temozolomide, and vincristine) for children and teens with solid tumors that have not responded to or have come back after standard treatment. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Hear when a new Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.